Received: 25 July 2021; Published on-line: 15 March 2022
Changes in the quantitative characteristics of the Ukrainian market of tear replacement products for dry eye disease over 2016-2019
V. M. Sakovych 1, Yu. O. Tomashevska 2, O. V. Makarenko 1, O. V. Kryvoviaz 2, M. S. Garnyk 2
1 Dnipro State Medical University; Dnipro (Ukraine)
2 Pirogov National Memorial Medical University, Vinnytsia; Vinnytsa (Ukraine)
TO CITE THIS ARTICLE: Sakovych V. M., Tomashevska Yu. O., Makarenko O. V., Kryvoviaz O. V., Garnyk M. S. Changes in the quantitative characteristics of the Ukrainian market of tear replacement products for dry eye disease over 2016-2019. J.ophthalmol.(Ukraine). 2022;1:58-62. http://doi.org/10.31288/oftalmolzh202215862
Background: Management of dry eye syndrome (DES) is a current medical, pharmaceutical and social issue both globally and in Ukraine.
Purpose: To assess changes in quantitative characteristics of the Ukrainian market of tear replacement products (TRPs) for dry eye disease over 2016-2019.
Material and Methods: Data from the national pharmacy-related registers and from PharmXplorer, a marketing research database from Proxima Research LLC, were used for research. Sales were assessed in terms of both packages and Ukrainian hryvnias (₴). Retrospective, structural and graphical methods were used for research.
Results: Of the TRPs available on the market, only 10.7% were Ukrainian products. Almost half (46.43%) of the TRPs were those whose price range was from ₴101 to ₴200. The smallest share of the market (14.28%) was attributed to the most expensive TRPs. In addition, almost half of the products of the lowest price range (₴100 and under) were domestic products.
Conclusion: the number of domestic TRPs in the Ukrainian pharmaceutical market is limited. A stable increase in TRP retail sales both in packages and hryvnias indicates a stable and positive increase in demand for therapeutic products for dry eye patients. A Ukrainian lowest-price niche medical device containing both dexpanthenol and taurin was an absolute leader of 2016-2019 TRP retail sales.
Keywords: tear replacement products, dry eye syndrome, retail sales, price niches
1.[Dry eye syndrome. Evidence-based clinical guidance]. [Internet]; 2019. Ukrainian. Available from: https://www.dec.gov.ua/wp-content/uploads/2019/11/2019_10_02_kn_syndrom_....
2.Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334-65..
3.Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II Report Executive Summary. Ocul Surf. 2017 Oct;15(4):802-12.
4.Bron AJ, de Paiva CS, Chauhan SK, Bonini S, Gabison EE, Jain S, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510.
5.Craig JP, Nichols KK, Akpek EK, Caffery B, DuaHS, Joo CK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276-83.
6.The management of dry eye. Drug Ther Bull. 2016;54(1):9-12.
7.Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575-628.
8.Willcox MDP, Argüeso P, Georgiev G, Holopainen J, Laurie G, Millar T, et al. TFOS DEWS II tear film report. Ocul Surf. 2017;15:366-403.
9.Friedman NJ. Impact of dry eye disease and treatment on quality of life. Current Opinion in Ophthalmology. 2010;21(4):310-6.
10.Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, et al. Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf. 2013;11(3):181-92.
11.Wolffsohn JS, Arita R, Chalmers R, Djalilian A, Dogru M, Dumbleton K, et al. TFOS DEWS II diagnostic methodology report. Ocul Surf. 2017;15:539-74.
12.Dogru M, Tsubota K. Pharmacotherapy of dry eye. Expert Opin Pharmacother. 2011 Feb;12(3):325-34.
13.Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Systematic Rev. 2016 Feb 23;2:CD009729.
14.U.S. Food, Drug Administration. Ophthalmic drug products for over‐the‐counter human use. www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=3... (accessed 26 August 2015).
15.Rodríguez-Pomar C, Pintor J, Colligris B, Carracedo G. Therapeutic inhibitors for the treatment of dry eye syndrome. Expert Opin Pharmacother. 2017 Dec;18(17):1855-1865. doi: 10.1080/14656566.2017.1403584. Epub 2017 Nov 14. PMID: 29115899.
16.Lee SY, Tong L. Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci. 2012;89(11):1654-1661.
17.Çakır B, Doğan E, Çelik E, Babashli T, Uçak T, Alagöz G. Effects of artificial tear treatment on corneal epithelial thickness and corneal topography findings in dry eye patients. J Fr Ophtalmol. 2018 May;41(5):407-411. doi: 10.1016/j.jfo.2017.06.032. PMID: 29776765.
18.Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eyedisease. Am J Ophthalmol. 2011;151(5):792-8.
19.Kryvoviaz OV, Tomashevska YuO. [Remedies for substitution therapy of the dry eye syndrome: analysis of the pharmaceutical market of Ukraine]. Pharmaceutical Review. 2019; 4, 37-44. Ukrainian.
20.[State Register of Medicines of Ukraine (2019)]. Available from: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlist?opendocument. Ukrainian.
21.[State Register of Medical Equipment and Medical Devices (2019)]. Available from: https://mozdocs.kiev.ua/medvyrob.php. Ukrainian.
22.Pharmxplorer. Proxima Research. 2012. Available from: http://www.pharmxplorer.com.ua. [Last accessed on 2020 Oct 01].
23.Tomashevska YuO, Kryvoviaz OV. Ensuring the sterility of substitution therapy medications for dry-eye syndrome treatment after opening the original packaging. Scientific journal of Polonia university. 2021;44(2021) nr 1:278-283.
Conflict of Interest Statement: The author states that there is no conflict of interest that could affect her opinion on the subject or materials of this manuscript.
Sources of Support: none.